Pharmaceutical

Celltrion’s SteQeyma receives EC approval for chronic inflammatory diseases

The European Commission (EC) has approved Celltrion's SteQeyma, a biosimilar to Stelara, for treating chronic inflammatory conditions.

Aug 27, 2024 - 04:00
Celltrion’s SteQeyma receives EC approval for chronic inflammatory diseases
The European Commission (EC) has approved Celltrion's SteQeyma, a biosimilar to Stelara, for treating chronic inflammatory conditions.
Read the original article

Tags:

Previous Article

MSD snags European approval for pulmonary arterial hypertension therapy

Next Article

Invenra’s antibody gains US FDA designations for neuroblastoma treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AB-1003 by Asklepios BioPharmaceutical for Limb-Girdle Muscular Dystrophy: Likelihood of Approval

AB-1003 by Asklepios BioPharmaceutical for Limb-Girdle ...

Nov 2, 2023

Novaliq’s dry eye disease therapy receives US FDA approval

Novaliq’s dry eye disease therapy receives US FDA approval

Jun 9, 2023

STAT+: How to ‘break the logjam’? Economists pitch a plan to curb dire drug shortages

STAT+: How to ‘break the logjam’? Economists pitch a pl...

Jul 12, 2023